To date, @entity2 is still the leading cause of @entity5 -related mortality worldwide, with the majority of @entity2 arising in the elderly. As a consequence, we can expect an increase in the number of older @entity2 @entity1 considered suitable for chemotherapy in the near future. Elderly @entity1 often have comorbid conditions and progressive physiologic reduction of organ function, which can make the selection of proper treatment daunting. Some @entity1 will be able to tolerate chemotherapy as well as their younger counterparts, whereas others will experience severe @entity137 and require treatment modifications. Thus, a major issue is effectively selecting @entity1 suitable for standard or attenuated therapy. A comprehensive geriatric assessment performed at baseline is a useful tool that can help select the best treatment regimen to be administered to elderly @entity1 . Until now, few trials have specifically focused on elderly @entity1 affected by @entity1149 ( @entity1149 ), particularly those with advanced disease; prospective elderly-specific studies in early stages are still lacking. High priority should be given to evaluating the role of new targeted therapies. Unfortunately, to date, clinical trials that include functional status and comorbidity as part of the geriatric assessment are rare. Future trials, specifically in the elderly population, should include these kinds of evaluations. The most recent therapies for the treatment of elderly @entity1 with @entity1149 will be discussed here.

XXXX therapy in the elderly.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancers', 'lung cancer'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']
@entity1149 :: (MESH:D002289,Disease) :: ['Non-small cell lung cancer']
